Skip to main content

Advertisement

SpringerLink
Log in

Retrospective analysis of prognosticators in patients with relapsed Hodgkin’s Lymphoma treated with autologous transplant: results of a single center

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Hodgkin’s Lymphoma (HL) is highly chemoresponsive, and majority of patients respond to therapy except for a small number which require high-dose therapy and stem cell rescue for salvage. We report the results of a single-center experience in 41 patients with relapsed HL treated with high-dose therapy at the time of relapse from the year 1989–2010. The 7-year OS for the group is 39.2 %; the median progression-free survival is 30.6 months. Univariate analysis identified refractory disease at transplant and extranodal involvement as important prognosticators. The 100-day mortality was 5 %. The most common cause for delayed mortality was disease progression. The incidence of secondary malignancy in the group was 2 %. Our results reinforce the significance of long-term follow up as late relapses are observed. Additionally, identifying biological prognosticators and implying them for treatment may improve the outcomes in poor-risk patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–84.

    Article  PubMed  CAS  Google Scholar 

  2. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s Lymphoma Study Group. Ann Oncol. 1997;8(2):143–8.

    Article  PubMed  CAS  Google Scholar 

  3. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol. 1992;10(2):210–8.

    PubMed  CAS  Google Scholar 

  4. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood. 1993;81(5):1137–45.

    PubMed  CAS  Google Scholar 

  5. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17(2):534–45.

    PubMed  CAS  Google Scholar 

  6. Josting A, Katay I, Rueffer U, Winter S, Tesch H, Engert A, et al. Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol. 1998;9(3):289–95.

    Article  PubMed  CAS  Google Scholar 

  7. Smith SD, Moskowitz CH, Dean R, Pohlman B, Sobecks R, Copelan E, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol. 2011;153(3):358–63.

    Article  PubMed  Google Scholar 

  8. Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Holowiecki J, et al. Outcome and prognostic factors in advanced Hodgkin’s disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol. 2004;15(8):1222–30.

    Article  PubMed  CAS  Google Scholar 

  9. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89(3):801–13.

    PubMed  CAS  Google Scholar 

  10. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol. 1999;17(10):3101–9.

    PubMed  CAS  Google Scholar 

  11. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106(4):1473–8.

    Article  PubMed  CAS  Google Scholar 

  12. Keller SF, Kelly JL, Sensenig E, Andreozzi J, Oliva J, Rich L, et al. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin’s lymphoma (HL) in the ABVD therapeutic era. Biol Blood Marrow Transplant. 2012;18(4):640–7.

    Article  PubMed  Google Scholar 

  13. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med. 2010;362(10):875–85.

    Article  PubMed  CAS  Google Scholar 

  14. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J Clin Oncol. 1989;7(11):1630–6.

    PubMed  CAS  Google Scholar 

  15. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14(4):418–25.

    Article  PubMed  CAS  Google Scholar 

  16. Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH. Successful treatment of refractory Hodgkin’s disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989;73(1):340–4.

    PubMed  CAS  Google Scholar 

  17. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol. 2002;13(Suppl 1):52–6.

    Article  PubMed  Google Scholar 

  18. Kim LH, Nadarajah VS, Peh SC, Poppema S. Expression of Bcl-2 family members and presence of Epstein-Barr virus in the regulation of cell growth and death in classical Hodgkin’s lymphoma. Histopathology. 2004;44(3):257–67.

    Article  PubMed  CAS  Google Scholar 

  19. Tedder TF, Klejman G, Schlossman SF, Saito H. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol. 1989;142(7):2560–8.

    PubMed  CAS  Google Scholar 

  20. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24(13):2121–43.

    Article  PubMed  CAS  Google Scholar 

  21. Pinkus GS, Said JW. Hodgkin’s disease, lymphocyte predominance type, nodular–further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker. Am J Pathol. 1988;133(2):211–7.

    PubMed  CAS  Google Scholar 

  22. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20(5):1278–87.

    Article  PubMed  CAS  Google Scholar 

  23. von Wasielewski R, Mengel M, Fischer R, Hansmann ML, Hubner K, Franklin J, et al. Classical Hodgkin’s disease. Clinical impact of the immunophenotype. Am J Pathol. 1997;151(4):1123–30.

    Google Scholar 

  24. Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz A, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin’s disease. Br J Haematol. 2004;125(6):701–8.

    Article  PubMed  Google Scholar 

  25. Bolwell BJ, Kalaycio M, Goormastic M, Dannley R, Andresen SW, Lichtin A, et al. Progressive disease after ABMT for Hodgkin’s disease. Bone Marrow Transplant. 1997;20(9):761–5.

    Article  PubMed  CAS  Google Scholar 

  26. Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin’s disease. Blood. 1998;92(6):1933–40.

    PubMed  CAS  Google Scholar 

  27. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23(31):7994–8002.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported in part by grants from the institution, Mount Sinai School of Medicine.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplant, The Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY, USA

    Aisha Masood, Amir Steinberg, Adriana Malone, Eileen Scigliano, Jacqueline Nieto, Keren Osman, Celia Grosskreutz & Luis Isola

  2. Preventive Medicine, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA

    Erin Moshier

  3. Lymphoma, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA

    Joshua Brody

Authors
  1. Aisha Masood
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erin Moshier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adriana Malone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eileen Scigliano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jacqueline Nieto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keren Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Celia Grosskreutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Luis Isola
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Joshua Brody
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aisha Masood.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masood, A., Steinberg, A., Moshier, E. et al. Retrospective analysis of prognosticators in patients with relapsed Hodgkin’s Lymphoma treated with autologous transplant: results of a single center. Med Oncol 30, 431 (2013). https://doi.org/10.1007/s12032-012-0431-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-012-0431-5

Keywords

Search

Navigation